 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Commonwealth Biotechnologies, Inc.
 |
Commonwealth Biotechnologies, Inc. |
 |
 |
 |
PROFILE |
 |
Commonwealth Biotechnologies, Inc. (CBI), working for the good of all, provides research and development services to biotechnology companies, academic institutions, and government agencies. Operating on both short- and long-term contractual bases, CBI serves nearly 2,000 customers worldwide. Services include DNA analyses, genome, peptide, and protein sequencing, and drug discovery. The company also performs genetic identity and paternity testing. CBI is developing its HepArrest technology to reverse the effects of blood-thinner heparin during surgery. Investor James Martin owns about 35% of the firm, while former director Charles Mill III owns about 25%.
COMPETITION |
 |
Albany Molecular Research, Inc. (AMRI)
Celera Genomics Group (CRA)
Quest Diagnostics Incorporated (DGX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 4.40
1-Yr. Sales Growth: 69.2%
Employees: 43
Revenue per employee: $102,325.58
KEY PEOPLE |
 |
Robert B. Harris
CEO
James H. Brennan
CFO
CONTACT INFO |
 |
601 Biotech Dr.
Richmond, VA 23235
US
Phone: 804-648-3820
Fax: 804-648-2641
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |